Tianda Pharmaceuticals マネジメント

マネジメント基準チェック /34

Tianda Pharmaceuticalsの CEO はAlan Fangで、 Feb2017年に任命され、の在任期間は 7.75年です。は、会社の株式の56.72%を直接所有しており、その価値はHK$ 225.62M 。経営陣と取締役会の平均在任期間はそれぞれ7.8年と11.2年です。

主要情報

Alan Fang

最高経営責任者

HK$60.0k

報酬総額

CEO給与比率	n/a
CEO在任期間	7.8yrs
CEOの所有権	56.7%
経営陣の平均在職期間	7.8yrs
取締役会の平均在任期間	11.2yrs

経営陣の近況

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

Oct 28

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

CEO（最高経営責任者

Alan Fang (55 yo)

7.8yrs

在職期間

HK$60,000

報酬

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Wen Quan Fang	Executive Chairman & MD	7.8yrs	HK$60.00k	56.72% HK$ 225.6m
Man Sang Lui	Executive Director	11.2yrs	HK$72.00k	データなし
Man Yuk Wong	Financial Controller	4.8yrs	データなし	データなし
Tai On Lo	Company Secretary	no data	データなし	データなし

7.8yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: 455の経営陣は経験豊富で経験豊富です（平均在職期間は7.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Wen Quan Fang	Executive Chairman & MD	21.1yrs	HK$60.00k	56.72% HK$ 225.6m
Man Sang Lui	Executive Director	11.2yrs	HK$72.00k	データなし
Sung Hong Chiu	Independent Non-Executive Director	16.6yrs	HK$72.00k	データなし
Yat-Fai Lam	Independent Non-Executive Director	20.2yrs	HK$72.00k	データなし
Tao Zhong	Non-Executive Director	1.3yrs	HK$25.00k	データなし
Quanming Feng	Non-Executive Director	8.7yrs	データなし	データなし
Yanfang Xian	Independent Non-executive Director	1.4yrs	HK$37.00k	データなし

11.2yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 455の取締役会は経験豊富で経験豊富です ( 11.2年の平均在任期間)。

Tianda Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Announces Board Changes

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Recent updates

Lacklustre Performance Is Driving Tianda Pharmaceuticals Limited's (HKG:455) 25% Price Drop

First half 2024 earnings released

New major risk - Financial data availability

New major risk - Financial position

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34